GetPortalImpactFactorByIdResp(projectId=1, id=884b2391, cover=https://img.medsci.cn/images/journal/cover/2021/TAx_202109271315018450.jpg, fullname=Expert Review of Anticancer Therapy, abbr=EXPERT REV ANTICANC, pyear=2001, frequence=Bimonthly, articleNumbers=1340, citedSelf2015=1.6, acceptanceRate=null, submissionToAcceptance=null, averageReviewTime=平均9月, reviewFee=null, pageFee=null, publishedRatio=2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%), issn=1473-7140, greenSci=https://www.greensci.net/search?kw=1473-7140, scijournal=https://www.scijournal.org/impact-factor-of-EXPERT-REV-ANTICANC.shtml, medsciHotlightString=null, medsciHotlightRealtime=3.404, medsciHotlight=3.471, medsciHotlight5year=3.635, citescore=6.4, hIndex=69, impactFactor=3.3, orgnization=Taylor and Francis Ltd., orgnizationUrl=http://www.future-drugs.com/, country=United Kingdom, countryCn=英国, isOa=3, isOaString=部分OA, sciScie=Science Citation Index Expanded|Current Contents - Clinical Medicine, bigclassCas=医学 4区, smallclassCas=医学 3 区, website=https://www.tandfonline.com/toc/iery20/current#.V48dKEz9cSQ, websiteHits=9185, guideForAuthor=null, guideForAuthorHits=18, submitWebsite=https://mc.manuscriptcentral.com/ert, submitWebsiteHits=2076, content=Published by Future-Drugs. ISSN: 1473-7140.<br /><br />Expert Review of Anticancer Therapy provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care., totalCites=4425, brief=EXPERT REV ANTICANC杂志医学行业，“<strong><a target="_blank" href="/sci/index.do?smallclass=肿瘤学" >肿瘤学</a></strong>”子行业的偏低级别杂志, articleType=本刊可能只接收综述类文章或很多文章不被WOS收录, medsciHeat=<span style="color: #990000;">暗红</span>, medsciComment=EXPERT REV ANTICANC杂志级别还可以，但是相对来说，比较冷门，关注人数偏少，有些可能是国内不太熟悉，但该杂志在国际仍然有相当知晓度的。因为缺少中国人投稿，稿源可能未必丰富，发表有可能有很大的机会哦。, medsciExplanation=MedSci期刊指数是根据中国科研工作者（含医学临床，基础，生物，化学等学科）对SCI杂志的认知度，熟悉程度，以及投稿的量等众多指标综合评定而成。当然，具体的，您还可以结合“<a href='https://www.medsci.cn/sci/submit.do?id=884b2391'>投稿经验系统</a>”，进行综合判断，这更是大家的实战经验，值得分享和参考。<br> 注意，上述MedSci期刊指数采用MedSci专利技术，由计算机系统自动计算，并给出建议，存在不准确的可能，仅供您投稿选择杂志时参考。, tags=[ImpactFactorTagDto(id=119, tagName=肿瘤, createdHits=3)], citeScoreList=[GetImpactFactorCiteScoreListResponse(year=2016, citescore=1.8), GetImpactFactorCiteScoreListResponse(year=2017, citescore=1.87), GetImpactFactorCiteScoreListResponse(year=2018, citescore=2.14), GetImpactFactorCiteScoreListResponse(year=2019, citescore=4.9), GetImpactFactorCiteScoreListResponse(year=2020, citescore=6.4)], medsciIndexList=[GetImpactFactorMedsciIndexListResponse(year=2020, medsciHotlight=5.287), GetImpactFactorMedsciIndexListResponse(year=2021, medsciHotlight=3.336), GetImpactFactorMedsciIndexListResponse(year=2022, medsciHotlight=3.517), GetImpactFactorMedsciIndexListResponse(year=2023, medsciHotlight=2.893), GetImpactFactorMedsciIndexListResponse(year=2024, medsciHotlight=3.404)], citeScoreGradeList=[GetImpactFactorCiteScoreGradeResponse(smallClass=Pharmacology (medical) , rank=63/237), GetImpactFactorCiteScoreGradeResponse(smallClass=Oncology , rank=106/331)], totalJcrAreaList=[GetImpactFactorCiteScoreGradeResponse(smallClass=ONCOLOGY - SCIE , rank=104/244)], pmcUrl=https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1473-7140[ISSN], pubmedUrl=https://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Expert Review of Anticancer Therapy[ta], article_number=125, article_number_cn=15, earlyWarning=null, linkOutUrl=null, isJournalMember=false, unscrambleContent=null, dayViewCount=false, endexampletyle=暂无数据)